Loading company…
Menlo Park-based ReCode Therapeutics develops genetic medicines for primary ciliary dyskinesia and cystic fibrosis.
Founded in 2015 in Menlo Park, California, ReCode Therapeutics, Inc. develops genetic medicines for genetically defined diseases with limited treatment options, including primary ciliary dyskinesia and cystic fibrosis. Its RCT2100 therapy received Orphan Drug Designation from the U.S. FDA for cystic fibrosis. The company was co-founded by Daniel Siegwart and Michael Torres and is led by CEO David Lockhart. In September 2025 it raised USD 29 million in venture debt funding from returning investor Cystic Fibrosis Foundation and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in